U.S. markets open in 3 hours 5 minutes

AC Immune SA (ACIU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.87-0.24 (-2.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close8.11
Open8.03
Bid0.00 x 800
Ask0.00 x 1200
Day's Range7.81 - 8.15
52 Week Range4.42 - 13.00
Volume296,256
Avg. Volume483,634
Market Cap571.777M
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.72
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile
    Benzinga

    AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile

    AC Immune SA (NASDAQ: ACIU) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No safety concerns or evidence for CNS inflammation or ARIA (amyloid-related imaging abnormalities) were observed, confirming earlier interim results. The company will complete the Phase 2 study with the 24-month analysis based on currently enrolled patients. The company is also advancing an optimized

  • AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
    GlobeNewswire

    AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

    Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease LAUSANNE, Switzerland, June 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided key clinical and preclinical updates for its Su

  • Is AC Immune (NASDAQ:ACIU) In A Good Position To Invest In Growth?
    Simply Wall St.

    Is AC Immune (NASDAQ:ACIU) In A Good Position To Invest In Growth?

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...